BackgroundBone is a common site of dissemination in advanced cancer accounting for one-third of all distant metastases. Various fractionation schedules of radiotherapy have been used for palliation of bone metastases. The aim of this study was to compare three schedules of external radiation therapy (8 Gy single session versus 20 Gy/5 fractions versus 30 Gy/10 fractions) for palliative management of bone metastases.MethodsIn the present study, 60 patients of bone metastases from any primary site were enrolled and randomly divided into three groups of 20 patients each by draw of lots. These patients received palliative external beam radiation therapy to the involved site. Patients were given 8 Gy single session, 20 Gy/5 fractions/1 week and 30 Gy/10 fractions/2 weeks in groups I, II and III, respectively.ResultsThe percentage of patients with overall pain relief was 80% in group I, 75% in group II and 85% in group III (P = 0.7). The number of patients with complete pain relief was 4 (20%) in each group. Maximum patients got pain relief at 4 weeks post-radiotherapy. The number of patients with improved performance status was 4 (20%) in group II and 2 (10%) each in groups I and III (P = 0.5). Thirteen (65%) patients in each of the groups had decreased analgesic requirement at 2-month follow-up. Retreatment rate was more in the single fraction (20%) compared to only 5% in group II and none in the group III (P = 0.05).ConclusionFrom the present study we conclude that 8 Gy single fraction is as effective as multifraction radiotherapy for the palliation of painful bone metastases. However, for a center like ours being the only Government Tertiary Cancer Care Centre in the State, general consensus drawn after this study, recommends external radiation therapy 20 Gy/5 fraction regimen to be an appropriate means of palliation of painful bone metastases.
BACKGROUND Exfoliative dermatitis (erythroderma) is an uncommon potentially serious inflammatory skin disorder characterized by an intense, widespread erythema and variable scaling. It results from aggravation of pre-existing skin disease, or may be caused by drugs or neoplasms. Although various paraneoplastic dermatoses may occur in association with carcinoma lung, erythroderma as the sole presenting feature is infrequently reported in literature. OBJECTIVE To emphasis on dermatological condition occurring simultaneously with malignancy and how it is to be managed while treating malignancy. METHODS Presenting a case of 55 years old female diagnosed with erythroderma along with moderately differentiated adenocarcinoma of rectum . After taking opinion from dermatologist it was diagnosed as erythroderma, which is a rare skin disorder and she developed this 4 months before diagnosing rectal cancer.. The case was discussed in disease management group as clinically.T3N2m0 where she was planned for neoadjuvant concurrent chemo radiation followed by assessment of surgery. Patient was planned for long course concurrent chemo radiation 50 Gy in 25 fractions for 5 weeks along with tab capecitabine 825mg/meter square/day .She was examined weekly during radiation therapy. After 18 fractions of radiation she started developed grade II radiation induced dermatitis, we admitted the patient and started intravenous fluids, local applications of ointment and injection dexamethasone in tapering dose after every 3 days starting from 16mg twice daily. Radiation was continued and slowly she starts improving, itching was reduced and lesions starts healing, the redness also become mild. Radiation was completed with no treatment break in radiation as well as chemotherapy IN B. RESULTS in this case study, the judicious use of steroids in tapering dose have an important role in controlling the flared up reactions. From previous reports on erythroderma, it has been treated with prednisolone and topical application of steroids. intravenous dexamethasone given in tapering doses resulted in controlling of the reactions at the local site itching has been reduced compared to previous state. CONCLUSIONS the case report is basically based on the management of erythroderma in a patient receiving concomitant chemoradiation ,by doing a close observation, support of intravenous steroids, proper hydration and nutrition. In this study treating the underlying malignancy along with managing the radiation induced erythroderma flare up during radiation therapy simultaneously without minimal treatment breaks. Some malignancies are associated with certain dermatological conditions, our main aim is to treat to malignancy with treatment of other comorbidities keeping in mind the skin reactions caused by radiation and treating the patient without any delay in radiation. CLINICALTRIAL NIL
Malignant nodular hidradenoma is very rare adnexal tumor with exceedingly low incidence of 0.001%. The biological behavior of the tumor is aggressive, with local recurrences reported in more than 50% of the surgically-treated cases. Treatment options are surgery and/or Radiotherapy. Till date there is no clear consensus on its treatment. We report a rare case of malignant nodular hidradenoma nose in an 80-years old male who responded miraculously to Radiotherapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.